These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
518 related items for PubMed ID: 10699072
1. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. Mehta RG, Williamson E, Patel MK, Koeffler HP. J Natl Cancer Inst; 2000 Mar 01; 92(5):418-23. PubMed ID: 10699072 [Abstract] [Full Text] [Related]
2. Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Tsujie M, Nakamori S, Okami J, Hayashi N, Hiraoka N, Nagano H, Dono K, Umeshita K, Sakon M, Monden M. Exp Cell Res; 2003 Sep 10; 289(1):143-51. PubMed ID: 12941612 [Abstract] [Full Text] [Related]
3. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Asou H, Verbeek W, Williamson E, Elstner E, Kubota T, Kamada N, Koeffler HP. Int J Oncol; 1999 Nov 10; 15(5):1027-31. PubMed ID: 10536188 [Abstract] [Full Text] [Related]
4. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. Cancer Res; 1998 Aug 01; 58(15):3344-52. PubMed ID: 9699665 [Abstract] [Full Text] [Related]
5. Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose. Rubin GL, Duong JH, Clyne CD, Speed CJ, Murata Y, Gong C, Simpson ER. Endocrinology; 2002 Aug 01; 143(8):2863-71. PubMed ID: 12130549 [Abstract] [Full Text] [Related]
6. Regulation of aromatase by nuclear receptors. Yanase T, Mu YM, Nishi Y, Goto K, Nomura M, Okabe T, Takayanagi R, Nawata H. J Steroid Biochem Mol Biol; 2001 Dec 01; 79(1-5):187-92. PubMed ID: 11850224 [Abstract] [Full Text] [Related]
7. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, Ishikawa A, Peabody T, Montag A, Simon MA, He TC. Clin Cancer Res; 2002 May 01; 8(5):1288-94. PubMed ID: 12006550 [Abstract] [Full Text] [Related]
11. Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. He BC, Chen L, Zuo GW, Zhang W, Bi Y, Huang J, Wang Y, Jiang W, Luo Q, Shi Q, Zhang BQ, Liu B, Lei X, Luo J, Luo X, Wagner ER, Kim SH, He CJ, Hu Y, Shen J, Zhou Q, Rastegar F, Deng ZL, Luu HH, He TC, Haydon RC. Clin Cancer Res; 2010 Apr 15; 16(8):2235-45. PubMed ID: 20371684 [Abstract] [Full Text] [Related]
16. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Cha BS, Ciaraldi TP, Carter L, Nikoulina SE, Mudaliar S, Mukherjee R, Paterniti JR, Henry RR. Diabetologia; 2001 Apr 15; 44(4):444-52. PubMed ID: 11357475 [Abstract] [Full Text] [Related]
20. Linkage between retinoid and fatty acid receptors: implications for breast cancer prevention. Stoll BA. Eur J Cancer Prev; 2002 Aug 15; 11(4):319-25. PubMed ID: 12195157 [Abstract] [Full Text] [Related] Page: [Next] [New Search]